Transcriptomics

Dataset Information

4

Expression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days


ABSTRACT: breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo. We used microarrays to compare gene expression changes of MCF7 breast xenograft treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days Breast xenograft MCF7 bearing mice treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days. RNA were extracted from tumors and hybridizedon Affymetrix microarrays to compare gene expression changes

ORGANISM(S): Homo sapiens  

SUBMITTER: Friedrich G Finckenstein   Fei Huang  Luciana F Macedo  Xiaonan Hou  Angela Brodie  Sean C Harrington  Joan M Carboni  Marco M Gottardis  Karen A Reeves  Ann Greer  Paul Haluska 

PROVIDER: E-GEOD-33366 | ArrayExpress | 2011-11-02

SECONDARY ACCESSION(S): GSE33366PRJNA149001

REPOSITORIES: GEO, ArrayExpress

Similar Datasets

2014-12-04 | E-GEOD-63857 | ArrayExpress
2016-07-01 | E-GEOD-79492 | ArrayExpress
2007-10-27 | E-GEOD-2225 | ArrayExpress
| GSE66607 | GEO
2012-12-21 | E-GEOD-31831 | ArrayExpress
2014-03-01 | E-GEOD-49124 | ArrayExpress
| GSE67916 | GEO
2010-01-01 | GSE17775 | GEO
2008-12-05 | E-GEOD-8141 | ArrayExpress
2016-05-25 | PXD001812 | Pride